Opposing roles for Set2 and yFACT in regulating TBP binding at promoters by Biswas, Debabrata et al.
Opposing roles for Set2 and yFACT in regulating
TBP binding at promoters
Debabrata Biswas1, Rinku Dutta-Biswas1,
Doyel Mitra1,4, Yoichiro Shibata2,
Brian D Strahl2, Tim Formosa3
and David J Stillman1,*
1Department of Pathology, University of Utah Health Sciences Center,
Salt Lake City, UT, USA, 2Department of Biochemistry and Biophysics,
University of North Carolina School of Medicine, Chapel Hill, NC, USA
and 3Department of Biochemistry, University of Utah Health Sciences
Center, Salt Lake City, UT, USA
Previous work links histone methylation by Set2 with
transcriptional elongation. yFACT (Spt16–Pob3 and
Nhp6) reorganizes nucleosomes and functions in both
transcriptional initiation and elongation. We show that
growth defects caused by spt16 or pob3 mutations can
be suppressed by deleting SET2, suggesting that Set2 and
yFACT have opposing roles. Set2 methylates K36 of histone
H3, and K36 substitutions also suppress yFACT mutations.
In contrast, set1 enhances yFACT mutations. Methylation
at H3 K4 by Set1 is required for set2 to suppress yFACT
defects. We did not detect an elongation defect at an 8 kb
ORF in yFACT mutants. Instead, pob3 mutants displayed
reduced binding of both pol II and TBP to the GAL1
promoter. Importantly, both GAL1 transcription and pro-
moter binding of pol II and TBP are significantly restored
in the pob3 set2 double mutant. Defects caused by an spt16
mutation are enhanced by either TBP or TFIIA mutants.
These synthetic defects are suppressed by set2, demon-
strating that yFACT and Set2 oppose one another during
transcriptional initiation at a step involving DNA binding
by TBP and TFIIA.
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Introduction
Eukaryotic DNA is packaged into highly compacted chroma-
tin, limiting the accessibility of transcription factors to DNA.
DNA sequences within chromatin can be made accessible to
transcription factors in several ways. First, ATP-dependent
chromatin remodeling factors can use the energy of ATP
to move nucleosomes and expose the DNA sequences for
transcription factor binding (Cairns, 2005). Second, variant
histones can be inserted into nucleosomes, resulting in
chromatin with altered properties (Kamakaka and Biggins,
2005). Third, nucleosomes can be altered by post-transla-
tional modifications, including acetylation, methylation and
ubiquitylation of lysine residues and phosphorylation of
serine residues (Strahl and Allis, 2000; Peterson and Laniel,
2004). These modifications may directly change the proper-
ties of chromatin, thereby aiding factor binding, and they
may create recognition sites for other factors such as bromo-
domain- and chromodomain-containing proteins that recog-
nize acetylated and methylated lysines, respectively.
We have been studying a fourth mechanism that enhances
accessibility of binding sites, the ATP-independent reorgani-
zation of nucleosomes by yFACT (Formosa, 2003).
Mammalian FACT contains two subunits, hSpt16 and
SSRP1, which are homologous to Spt16 and Pob3 in yeast,
except that SSRP1 has a single HMGB DNA-binding motif
at its C-terminus that is missing from Pob3 (Wittmeyer and
Formosa, 1997; Orphanides et al, 1999). The yeast Nhp6
protein, essentially a single HMGB domain, supports the
ability of Spt16–Pob3 to function as yFACT both in vitro
and in vivo (Brewster et al, 2001; Formosa et al, 2001).
There is substantial evidence linking yFACT to transcriptional
elongation. For example, several yFACT mutants are sensitive
to the elongation inhibitor 6-azauracil (6-AU) (Orphanides
et al, 1998; Formosa et al, 2001) and show genetic interac-
tions with known elongation factors (Formosa et al, 2002;
Squazzo et al, 2002). In addition, yFACT physically associates
with several elongation factors (Krogan et al, 2002; Squazzo
et al, 2002; Simic et al, 2003), human FACT facilitates RNA
polymerase II (pol II) elongation through a chromatin
template in vitro (Orphanides et al, 1998), and ChIP and
immunolocalization studies show association of FACT with
elongating pol II (Mason and Struhl, 2003; Saunders et al,
2003).
In addition to a role in transcript elongation, experiments
also suggest that yFACT has a role in regulating transcrip-
tional initiation. An spt16 mutation can change the site of
transcriptional initiation (Malone et al, 1991), and Drosophila
FACT associates with the GAGA factor and stimulates
chromatin changes at promoters (Shimojima et al, 2003).
Spt16 inactivation in yeast results in reduced binding of TBP
and TFIIB at promoters, spt16 mutants show strong genetic
interactions with mutations affecting TBP and TFIIA, and
yFACT facilitates TBP and TFIIA binding to nucleosomal
binding sites in vitro (Mason and Struhl, 2003; Biswas et al,
2005). yFACTcan, therefore, enhance the accessibility of DNA
sequences in chromatin (Formosa et al, 2001), and this is
an important component of transcriptional regulation both
during initiation and elongation. yFACT also interacts with
DNA polymerase a, and with MCM proteins, and it plays an
important role in DNA replication (Wittmeyer et al, 1999;
Gambus et al, 2006; VanDemark et al, 2006).
Histone proteins are methylated by SET domain-containing
proteins, and histone methylation can regulate transcription
(Lee et al, 2005; Martin and Zhang, 2005). In yeast, histone
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H3 is methylated at K4, K36 and K79 by the Set1, Set2, and
Dot1 histone methyl transferases, respectively. It has been
suggested that K4 methylation by Set1 facilitates transcrip-
tional elongation, as K4 methylation is enriched in the
transcribed regions of actively transcribed genes (Liu et al,
2005; Pokholok et al, 2005), and Set1 is recruited to elon-
gating RNA polymerase complexes (Ng et al, 2003). These
observations suggest that Set1 is a positive elongation factor.
Di- and tri-methylation at K36 by Set2 is also found at
transcribed open reading frames (Liu et al, 2005; Pokholok
et al, 2005; Rao et al, 2005). Set2 also associates with the
elongating form of RNA polymerase (Krogan et al, 2003; Li
et al, 2003; Xiao et al, 2003). Moreover, set2 mutants show
synthetic growth defects with genes implicated in elongation,
consistent with Set2 also being a positive elongation factor
(Krogan et al, 2003; Li et al, 2003). However, several
observations are more consistent with a negative role for
Set2 in regulating transcription initiation. K36 methylation by
Set2 is required to recruit the Rpd3S histone deacetylase
complex through its Eaf3 chromodomain subunit, and de-
acetylation by Rpd3S may be required to restore chromatin to
the repressed pretranscribed state (Carrozza et al, 2005; Joshi
and Struhl, 2005; Keogh et al, 2005). Set2 represses transcrip-
tion when tethered to a heterologous promoter, indicating
a direct negative effect on initiation (Strahl et al, 2002).
Additionally, expression of a mutant GAL4 promoter lacking
its UAS element is very low, but can be increased either by a
set2 mutation or a histone H3 K36R substitution, suggesting
that modification of H3 by Set2 inhibits initiation (Landry
et al, 2003). Importantly, although several studies have
shown greater K36 methylation at open reading frames
(Pokholok et al, 2005; Rao et al, 2005), it is clear that K36
methylation also occurs in promoter regions (Xiao et al,
2003). Set2 therefore has complex and perhaps opposite
effects on different stages of transcriptional regulation.
In this report, we show that yFACT and K36 methylation
by Set2 have opposing roles in regulating transcription.
Surprisingly, we find no evidence that mutations affecting
yFACT and Set2 influence transcriptional elongation rates.
Instead, our results show that yFACTand histone methylation
by Set2 regulate, in opposite ways, binding of both pol II and
TBP to promoters.
Results
Set1 methylation at histone H3 K4 supports the function
of yFACT
SPT16 and POB3 are essential genes, and mutant alleles with
distinct phenotypes have been isolated (Malone et al, 1991;
Rowley et al, 1991; Schlesinger and Formosa, 2000; Formosa
et al, 2001). We chose the spt16-11 and pob3(L78R) alleles for
these studies because they display the Spt-phenotype from
inappropriate TATA element usage, and they are sensitive to
elevated temperatures, to the dNTP synthesis inhibitor hydroxy-
urea (HU), and to the transcription elongation inhibitor 6-AU.
Thus, the phenotypes of the spt16-11 and pob3(L78R) alleles
suggest that they have defects in transcriptional initiation,
transcriptional elongation, as well as in replication of DNA.
We previously showed that some yFACT mutations are
synthetically lethal with some mutations in histone H3 and
H4, including deletions of the N-terminal tails and mutations
of certain acetylatable lysine residues (Formosa et al, 2002;
VanDemark et al, 2006). Here, we look for genetic inter-
actions between yFACT mutations and H3 mutations in
methylated lysines K4 and K79, and acetylated site K23.
Strains with deletions of both sets of chromosomal genes
encoding histone H3 and H4, and carrying a YCp-URA3
plasmid with the wild-type HHT2–HHF2 genes were
constructed. Plasmids with either wild-type or mutant
HHT2-HHF2 alleles were introduced into these strains by
transformation, and the ability of transformants to grow
on media with FOA was assessed. URA3þ strains cannot
grow on FOA, and thus growth demonstrates that the
wild-type histone genes on the YCp-URA3 plasmid can be
lost with the introduced plasmid supporting viability.
As shown in Figure 1A, introducing plasmids with wild-
type histones, H3(K4R), H3(K23R), or H3(K79R) into a
wild-type strain results in healthy growth, while the empty
vector does not. We conclude that these H3 mutations sup-
port viability in a wild-type strain, the H3(K23R) mutation
shows a modest growth defect in combination with either an
spt16-11 (Figure 1B) or a pob3(L78R) (Figure 1C) mutation,
































Figure 1 Histone H3(K4R) substitutions enhance the defects
caused by spt16 and pob3 mutations. (A) Strain DY7803 was
transformed with a YCp-TRP1 plasmid with wild-type histone H4
gene and the indicated histone H3 mutation, and dilutions were
plated on the indicated medium for 2 days at 331C. (B) As in panel
(A), except the strain is DY7809. (C) As in (A) except the strain
is DY7818 and dilutions were incubated for 3 days at 251C.
(D) Dilutions of strains DY150, DY8788, DY8875, and DY9206 were
plated on complete medium at 251C for 3 days or at 331C for 2 days.
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H3(K4R) mutation has a more striking effect, showing a
strong synthetic defect when combined with either spt16
or pob3. Lysine 4 of histone H3 is methylated by the Set1
enzyme (Briggs et al, 2001), and thus we predict a similar
effect from a set1 mutation. We constructed an spt16 set1
double mutant and found it to be viable at 251C, but lethal
at 331C (Figure 1D). We were unable to construct a pob3
set1 double mutant, as it was lethal at all temperatures tested.
We conclude that the function of yFACT is strongly dependent
on methylation of histone H3 at K4 by Set1.
Absence of Set2 methylation at histone H3 K36
suppresses temperature sensitivity caused by yFACT
mutations
In contrast with our results with the K4R mutation, we found
that mutations at histone H3 K36 suppress growth defects
associated with yFACT mutations. The spt16-11 mutant does
not grow at 351C, as evidenced by its failure to grow on FOA
when containing a plasmid with wild-type histone genes
(Figure 2A). However, the spt16 mutant grows on FOA if
the plasmid contains either a K36R or a K36A mutation in
histone H3. Similarly, a strain with the pob3(L78R) allele is
unable to grow at 301C, but the H3 K36R or K36A mutations
suppress this growth defect (Figure 2B). To verify that this
apparent growth suppression was not an artefact of growth
on FOA-containing medium, we used a plasmid shuffle at
251C to evict the YCp-URA3 plasmid, obtaining strains with a
YCp-TRP1 plasmid with either wild-type histone genes or a
derivative with the H3(K36A) substitution. The spt16 mutant
with wild-type histone H3 is unable to grow at 351C, but the
K36A substitution suppresses (Figure 2C). Similarly, histone
H3(K36A) suppresses the pob3 mutant (Figure 2D).
The Set2 enzyme methylates K36 of histone H3 (Strahl
et al, 2002), so if methylation at this site by Set2 is the cause
of the suppression, a set2 mutation should have a similar
phenotype to an H3 K36 mutation. As shown in Figure 2E and
F, a set2 gene deletion also suppresses the temperature
sensitivity of the spt16 and pob3 strains. These observations
clearly indicate that Set2 methylation of histone H3 at K36
has an opposing role to that of yFACT in supporting viability.
Opposing roles of Set1 and Set2 methyltransferases
The temperature-sensitive growth defect in an spt16 mutant
is affected by set1 and set2 mutations, but in opposite
directions. To examine the epistasis relationships, we con-
structed an spt16 set1 set2 triple mutant. The results in
Figure 3A show that the triple mutant has a marked growth
defect, although not quite as severe as the spt16 mutant or the
spt16 set1 double mutant. We next constructed a plasmid
with both histone H3 K4R and K36R mutations and tested it
in the spt16 and pob3 mutants. The results in Figure 3B show
that the H3(K4R,K36R) double mutant is synthetically lethal
with both spt16 and pob3, the same phenotype seen with
K4R. Thus, the K4R mutation is epistatic to K36R. We
conclude that the absence of Set2 methylation at H3 K36
can only suppress the yFACT defects when methylation by
Set1 occurs at H3 K4.
Histone mutations affect growth in nhp6ab mutant
strains
In addition to Spt16 and Pob3, yFACT contains Nhp6, a small
HMG protein required for nucleosomal binding by Spt16–
Pob3 (Formosa et al, 2001). Nhp6 is encoded by two redun-
dant genes, NHP6A and NHP6B, and the nhp6ab double
mutant shows growth defects. We next examined the effect
of histone mutations on an nhp6ab strain. Similar to the
















































Figure 2 Histone H3(K36) substitutions and set2 mutations sup-
press spt16 and pob3 mutations. (A) Strain DY7809 was trans-
formed with a YCp-TRP1 plasmid with wild-type histone H4 gene
and the indicated histone H3 mutant, and dilutions were plated on
complete medium (2 days) or FOA medium (3 days) at 351C. (B) As
in (A), except the strain is DY7818 and dilutions were plated
on complete medium (3 days) or FOA medium (5 days) at 301C.
(C) Dilutions of Strains DY8862, DY8864, DY8865, and DY8867 were
plated on complete medium at the indicated temperature for 3 days.
(D) Dilutions of strains DY8862, DY8864, DY10468, and DY10469
were plated on complete medium at the indicated temperature for 3
days. (E) Dilutions of strains DY150, DY8690, DY8787, and DY8790
were plated on complete medium at the indicated temperature for 2
days. (F) Dilutions of strains DY150, DY8690, DY8881, and DY8878
were plated on complete medium at 251C for 2 days or at 301C
for 3 days.
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caused a severe synthetic defect with nhp6ab (Figure 3C) and
H3(K79) mutations had no effect (not shown). However, the
H3(K36) substitutions had a markedly different effect in the
nhp6ab mutant; instead of the suppression seen with spt16
and pob3, the K36 mutations inhibited growth of the nhp6ab
strain. A synthetic growth defect is also seen when a set2
mutation is introduced into a nhp6ab strain (data not
shown). In addition to its role in yFACT, Nhp6 has been
shown to interact with other chromatin proteins, including
Swi/Snf, RSC, and Ssn6/Tup1 (Szerlong et al, 2003; Biswas
et al, 2004; Fragiadakis et al, 2004) and to play a role in
transcription by RNA polymerase III (Kassavetis and Steiner,
2006). These additional roles for Nhp6 could explain why the
H3(K36) mutations have such markedly different effects in
the nhp6ab strain compared to the spt16 and pob3 mutants.
A variety of yFACT mutant defects are suppressed
by set2
spt16-11 mutants are defective for growth on media contain-
ing 6-AU (Formosa et al, 2001). 6-AU is a uracil analog that
causes imbalances in the pools of rNTPs (Exinger and
Lacroute, 1992; Shaw and Reines, 2000), and many strains
with defects in transcriptional elongation are sensitive to
6-AU. We determined whether the 6-AU sensitivity caused
by spt16 could be suppressed either by a histone mutation
or by a set2 mutation. As shown in Figure 4A, the 6-AU
sensitivity of the spt16 strain (line 4) is suppressed by a K36A
substitution in histone H3 (line 6). A set2 mutation similarly
suppresses the 6-AU sensitivity caused by spt16 (Figure 4B).
We note that set2 mutants display slightly higher 6-AU
resistance than wild-type strains, consistent with previous
reports (Adhvaryu et al, 2005; Keogh et al, 2005; Kizer et al,
2005). Thus, spt16 and set2 mutants have opposite responses
to 6-AU, suggesting that yFACT and Set2 have opposing roles
in transcriptional elongation. However, sensitivity to 6-AU
does not necessarily demonstrate a role in transcriptional
elongation; a mutation in the SNR6 promoter that reduces
expression of the U6 small nuclear RNA causes 6-AU sensi-
tivity (Eriksson et al, 2004).
Based on the observation that a set2 mutation suppresses
the temperature- and 6-AU-sensitive phenotypes associated
with yFACT mutations, we tested whether set2 can also
suppress other synthetic defects observed with yFACT
mutants. An spt16 mutation displays synthetic defects with
mutations in either the GCN5 or the ELP3 histone acetyl-
transferase genes, or with the nhp6ab double mutant
(Formosa et al, 2002), and a set2 mutation suppresses all of
these synthetic growth defects (Supplementary Figure S1). It
has been proposed that the Isw1 chromatin remodeling factor
has a role in transcriptional elongation (Morillon et al, 2003).
A spt16 isw1 double mutant shows a synthetic growth defect
at 331C, and this is suppressed by set2 (Figure 4C). These
suppression results support the idea that yFACT and Set2


























Figure 3 set1 is epistatic to set2 in genetic interactions with spt16. (A) Dilutions of strains DY150, DY8787, DY8690, DY8875, DY8777, DY9178,
and DY9180 were plated on complete medium at 251C for 2 days or at 351C for 3 days. (B) Strains DY7809 and DY7818 were transformed with a
YCp-TRP1 plasmid with wild-type histone H4 gene and the indicated histone H3 mutant, and dilutions were plated and incubated as follows:
spt16 on complete, 2 days at 251C, spt16 on FOA, 4 days at 351C, pob3 on complete, 3 days at 251C, and pob3 on FOA, 5 days at 301C. (C) As in
(B), except the strains are DY7803 and DY7142, and dilutions were plated on the indicated medium at 331C for 4 days.
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The H2A.Z histone variant of H2A in yeast, encoded by
HTZ1 gene, has diverse functions (Dryhurst et al, 2004). We
constructed an spt16 htz1 double mutant strain, and observed
synthetic lethality at 331C (Figure 4D). This growth defect is
also suppressed by a set2 mutation. Importantly, genome
wide studies show that the Htz1 protein localizes preferen-
tially at the promoter regions of genes (Li et al, 2005; Raisner
et al, 2005; Zhang et al, 2005). This promoter localization of
Htz1, and the genetic interactions seen here, suggest that Set2
and yFACT might have opposing roles at promoter regions,
in addition to their proposed elongation functions.
Specificity of set2 suppression
We also tested whether set1 or set2 mutations also affect
other factors thought to be involved in transcriptional elon-
gation. We constructed double mutant strains, combining
either a set1 or a set2 mutation with disruptions in PAF1,
CDC73, DST1, SPT4, or ELP3. The double mutants with
set1 or set2 were examined for growth phenotypes, inclu-
ding sensitivity to temperature and 6-AU. There are some
instances of suppression and some of synthetic defects
(Supplementary Figure S2A). However, these elongation mu-
tants do not all show suppression with set2 and synthetic
defects with set1, and thus the effect appears to be specific to
spt16 and pob3.
spt16 mutants also cause an Spt-phenotype, altering tran-
scription start sites from the his4-912d and lys2-128d alleles
and conferring a Hisþ Lysþ phenotype (Malone et al,
1991). Interestingly, spt16 set2 strains are still Spt-, and
thus set2 does not suppress this phenotype (data not
shown). Similarly, the synthetic growth defect seen in a
spt16 rpd3 double mutant (Formosa et al, 2002) is not
suppressed by set2 (data not shown). However, we do see
suppression by set2 of the Spt-phenotype seen in a gcn5
mutant with the lys2-173R2 allele (Supplementary Figure
S1D). A set2 deletion, therefore, does not suppress all elonga-
tion defects, and it also does not suppress all of the defects
caused by yFACT mutations.
Pob3 and Set2 regulate GAL1 induction in opposing
ways
Mason and Struhl (2003) used a GAL1-YLR454w reporter,
with the GAL1 promoter inserted upstream of the nonessen-
tial 8 kb YLR454w gene, to show that yFACT associates with
open reading frames during transcription. We constructed
pob3 and set2 strains with this GAL1-YLR454w allele and
measured YLR454w mRNA levels by S1 nuclease protection
assays following induction of the GAL1 promoter. The results
in Figure 5A show a rapid increase in YLR454w mRNA in the
wild-type strain, as expected. The pob3 mutant strain is
markedly defective in inducing YLR454w mRNA from the
GAL1 promoter (Figure 5A), and a similar defect is seen
in induction of the native GAL1 gene in the pob3 mut-
ant (Figure 5B). Importantly, deletion of SET2 ameliorates
the transcriptional defect significantly at GAL1-YLR454w
(Figure 5A), and completely at GAL1 (Figure 5B) (compare
pob3 and pob3 set2). Additionally, we examined other genes
and found either an spt16 or pob3 mutation could reduce
expression, and a set2 mutation partially suppresses these
defects (Supplementary Figure S3A). These observations
imply that Set2 and yFACT have opposing roles in regulating
transcription.
While a set2 mutant caused decreased induction of GAL1-
YLR454w, it displayed increased expression before induction
(Figure 5C). Set2 is, therefore, needed both for repression of
the GAL1 promoter in this context and for normal induction
of expression, underscoring the complexity of the role of Set2
in transcription. Notably, Set2 is not needed for full induction
of the native GAL1 message (Figure 5B). It is possible that the
large size of the 8 kb YLR454w transcription unit places
a larger demand on Set2 function than the 1.6 kb GAL1 gene.
Defect in pol II binding to the GAL1 promoter in pob3
mutants
We used the GAL1-YLR454w reporter to assess the rate of pol
II elongation in wild-type and mutant strains in several ways.
In the first assay, we took RNA samples every 10 min follow-


































Figure 4 set2 suppress spt16 phenotypes. (A) set2 suppresses the
6-AU sensitivity caused by an spt16 mutation. Dilutions of strains
DY8883, DY8884, DY8885, DY8886, DY8887, and DY8888 were
plated at 251C on complete medium for 2 days or on medium
lacking uracil containing 50mg/ml 6-azauracil (6-AU) for 4 days.
(B) H3(K36A) suppresses the 6-AU sensitivity caused by an spt16
mutation. As in (A), except the strains are DY3398, DY8789,
DY8788, and DY8790. (C) set2 suppresses the spt16 isw1 synthetic
growth defect. Dilutions of strains DY150 (wild type), DY8107
(spt16), DY8690 (set2), DY8235 (isw1), DY9022 (spt16 isw1), and
DY9029 (spt16 isw1 set2) were plated on complete medium at the
indicted temperature for 3 days. (D) set2 suppresses the spt16 htz1
synthetic growth defect. Strains DY7836, DY9808, DY9805, and
DY8107 were plated on complete medium at the indicated tempera-
ture for 2 days.
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protection assays specific to the 50 and 30 ends of the gene.
The time between appearances of mRNA sequences corre-
sponding to the 50 and 30 ends gives an indication of how long
it takes for pol II to traverse the 8 kb gene. We do not see a
significant difference in this time in the wild-type, set2, pob3,
and pob3 set2 strains (Supplementary Figure S4). In a second
assay to measure elongation rates, glucose was added to cells
growing in galactose to shut down expression of GAL1-
YLR454w, and chromatin immunoprecipitation (ChIP) was
used to measure Pol II occupancy during the last wave of
transcription down the gene (Mason and Struhl, 2005). This
assay did not show any elongation defect in pob3 mutants
(Supplementary Figure S5). Thus, the marked defect in
GAL1-YLR454w expression in pob3 mutants is not due to an
elongation defect. Of course, pob3 mutants may be defective
for elongation at other genes.
We also used ChIP assays to measure pol II levels along the
YLR454w gene following galactose induction. Figure 6A
shows a map of the GAL1-YLR454w reporter, and four regions
amplified with specific primers corresponding to the
GAL1-YLR454w promoter, 1 kb downstream of start codon,
the middle of the YLR454w ORF (þ 3600), and the 30 end of
the gene (þ 7800). At time intervals following galactose
induction, samples were harvested, treated with formalde-
hyde to crosslink, and processed for ChIP. The results of the
pol II ChIP from the wild-type strain are shown in Figure 6B.
As expected, pol II occupancy increases throughout the gene
during induction. Pol II binding to the promoter is not
saturated during this time course, unlike previous results
(Bryant and Ptashne, 2003); there are important differences
in media and cell concentration between the two studies. A
delay is seen in pol II occupancy at þ 1000 and downstream,
reflecting the amount of time required to initiate and progress
through the ORF. For example, occupancy reaches a 30-fold
ratio after about 8 min at the promoter, 14 min at þ 1000, and
22 min at þ 7800. Notably, the time course is similar for a
pob3 mutant, although the overall occupancy is much lower
(Figure 6C). This is consistent with similar elongation rates at
GAL1-YLR454w in wild-type and pob3 strains; similar results
are seen with set2 and pob3 set2 strains (data not shown).
Examination of the wild-type strain shows that occupancy
at the promoter is much higher than it is at any point within
the ORF at all time points. Plotting the Pol II occupancy at the
50 min time point clearly shows this difference (Figure 6D).
Greater occupancy at the promoter suggests that recruitment
is faster than the transition from initiation to elongation
under these strongly inducing conditions. Pol II occupancy
at all sites decreases in both set2 and pob3 mutants, so Set2
and yFACT are both involved in recruiting Pol II to this
promoter. Interestingly, among the mutants, only the pob3
set2 strain has slightly higher pol II occupancy at the promo-
ter than at the ORF. Loss of the higher accumulation of Pol II
at the promoter compared to the ORF in the mutants might
indicate that Set2 and yFACTcooperate to impose a barrier or
selective elongation switch between recruitment and initia-
tion or elongation by Pol II. This functional cooperation
between Set2 and yFACT contrasts with the opposing roles
detected above.
Importantly, while a pob3 strain has a severe defect in pol
II occupancy at the at GAL1-YLR454w promoter, the set2 pob3
double mutant has a less severe defect, similar to the set2
single mutant (Figure 6D). The same effect is seen at the
native GAL1 promoter, where the set2 mutation does not by
itself cause diminished pol II occupancy (Figure 6E). Deletion
of SET2, therefore, at least partially restores the ability of
a pob3 mutant to recruit pol II to a promoter.
Defective TBP binding in pob3 mutants is suppressed
by set2
Pol II is typically recruited to promoters by the TATA-binding
protein TBP. We have previously shown that yFACTcan play a
role in transcriptional initiation through regulation of TBP
binding (Biswas et al, 2005), and we therefore examined TBP
binding to the GAL1-YLR454w promoter in these mutants. As
shown in Figure 6F, TBP binding to GAL1-YLR454w is essen-
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Figure 5 A set2 mutation reverses the poor induction of GAL1
caused by a pob3 mutation. Strains DY9591, DY9976, DY9972, and
DY9974 were grown on YP medium with 2% raffinose. Galactose
was added to 2% concentration, and samples were taken at
10 min intervals and mRNA measured by S1 nuclease protection.
(A) YLR454w mRNA levels from the GAL1-YLR454w allele.
(B) GAL1 mRNA levels. (C) YLR454w mRNA levels before galactose
induction.
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the pob3 set2 double mutant strain. We also found TBP
binding at other promoters is reduced in a pob3 mutant,
and increased TBP binding is seen in the pob3 set2 strain
compared to the pob3 single mutant (Supplementary Figure
S3B). Thus, TBP binding to the GAL1 promoter is stimulated
by yFACT, and the pob3 defect can be suppressed by a set2
mutation.
Pol II binding at GAL1-YLR454w is markedly reduced in the
set2 and pob3 set2 strains, while TBP binding is at wild-type
levels. Thus TBP binding is not sufficient to direct pol II
recruitment, and other factors such as TFIIA or TFIIB may
be involved.
The synthetic lethality between spt16 and either TBP
or TFIIA mutations is suppressed by set2
We previously demonstrated genetic interactions between
spt16 and TBP mutations (Biswas et al, 2005). We showed
that combining mutant Spt16 and mutant TBP proteins in the
same cell results in lethality, using a plasmid shuffle assay to
introduce mutant alleles into a strain lacking both SPT15
(which encodes TBP) and SPT16.
We have repeated this experiment, now including an
spt15D spt16D set2 YCp-URA3-TBP-Spt16 strain. As shown
in Figure 7A, certain combinations of Spt16 and TBP result in
lethality in SET2 strains, but a set2 mutation allows these
combinations of Spt16 and TBP to be viable. For example,
cells with spt16-11 and TBP(E93G) cannot lose the YCp-
URA3-TBP-Spt16 plasmid with the wild-type genes, as evi-
denced by the failure to grow on FOA, demonstrating the
synthetic lethality. In contrast, the set2 mutant with spt16-11
and TBP(E93G) can grow on FOA. Thus, set2 suppresses the
synthetic lethality between spt16 and TBP.
We also showed synthetic lethality between spt16 and
TFIIA mutations (Biswas et al, 2005). Yeast TFIIA protein is
composed of two subunits, Toa1 and Toa2. Based on the
TBP–TFIIA crystal structure, Ozer et al (1998) generated toa2
mutations at the TBP–TFIIA interface. Although these muta-
tions in TOA2 eliminate TBP–TFIIA interactions with in vitro
binding assays, the toa2 mutants are viable, presumably
because other factors present in cells facilitate TBP–TFIIA
interaction and DNA binding. For example, Toa2(W76) is
required for cooperative DNA binding with TBP in vitro, but
a toa2(W76A) mutant is viable in an otherwise wild-type
strain (Ozer et al, 1998; Biswas et al, 2005). The toa2(W76A)
allele is lethal in an spt16 mutant (Figure 7B). However,
toa2(W76A) is viable in the spt16 set2 strain, and thus set2
suppresses the synthetic lethality between spt16 and TFIIA
mutations.
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Figure 6 A pob3 mutation reduces pol II and TBP binding, and
binding is restored in a pob3 set2 strain. Strains DY9591, DY9976,
DY9972, and DY9974 were grown on YP medium with 2% raffinose.
Galactose was added to 2%, and samples were taken at 10 min
intervals and processed for ChIP analysis to measure pol II and
TBP binding. (A) Map of the GAL1-YLR454w allele showing the
positions of the PCR primers at the promoter and within the gene.
(B) Kinetics of pol II binding following galactose induction at
different GAL1-YLR454w regions in a wild-type strain. Error bars
show variance among replicate PCRs. (C) Kinetics of pol II binding
following galactose induction at different GAL1-YLR454w regions in
a pob3 strain. (D) Distribution of pol II at 50 min following galactose
induction at different GAL1-YLR454w regions in four different
strains. Error bars show variance among replicate PCRs. (E) Pol II
binding to the native GAL1 promoter at 30 min following galactose
induction in four different strains. Error bars show variance among
replicate PCRs. (F) TBP binding to the GAL1-YLR454w promoter
following galactose induction in four different strains. ChIP values
were normalized to binding at t¼ 0. Error bars show variance
among replicate PCRs.
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Suppression of the synthetic lethality between spt16 and
TBP or TFIIA mutants by deletion of SET2 strongly supports
our hypothesis that yFACT and Set2 have opposing roles in
supporting binding of TBP and TFIIA to promoters.
Discussion
Spt16 and Pob3, along with Nhp6, comprise the yFACT
complex that can reorganize chromatin structure. SPT16
and POB3 are essential genes, and spt16 and pob3 point
mutants have been isolated with phenotypes including tem-
perature-sensitive growth, sensitivity to 6-AU, and synthetic
lethality with certain transcription factor mutations. We find
that a set2 deletion, eliminating the enzyme that methylates
lysine 36 on histone H3, suppresses all of these phenotypes.
Additionally, a histone H3 mutation, replacing the lysine at
position 36 with either an alanine or an arginine residue, also
suppresses spt16 and pob3 mutations. We conclude that
methylation on histone H3 at K36 by Set2 acts in opposition
to the chromatin changes facilitated by yFACT. spt16 and
pob3 mutants also cause initiation at aberrant sites, leading
to the Spt- phenotype. This defect was not suppressed by
set2, indicating that not all functions of yFACT are opposed
by Set2.
Both Set2 and yFACT have been implicated in regulating
transcriptional elongation. Both localize preferentially to
transcribed regions compared to promoters (Krogan et al,
2003; Mason and Struhl, 2003; Saunders et al, 2003), Set2
associates with hyperphosphorylated pol II (Li et al, 2003;
Xiao et al, 2003), and several studies have shown greater K36
methylation at open reading frames compared to promoters
(Xiao et al, 2003; Pokholok et al, 2005; Rao et al, 2005).
Additionally, both spt16 and set2 mutations show genetic
interactions with known elongation factors (Formosa et al,
2002; Squazzo et al, 2002; Krogan et al, 2003; Li et al, 2003).
We looked for defects in transcriptional elongation in a pob3
mutant, using a strain with the GAL1 promoter inserted
upstream of the nonessential 8 kb YLR454w gene. We found
no evidence for a transcriptional elongation defect at GAL1-
YLR454w in pob3 mutants, but pob3 mutants may affect
elongation at other genes. We did find reduced expression
of both GAL1 and GAL1-YLR454w in the pob3 mutant.
Importantly, expression was restored in the pob3 set2 double
mutant.
ChIP experiments indicate that yFACT and Set2 act at the
GAL1 promoter at the level of transcriptional initiation.
Following galactose induction, there is reduced binding of
both pol II and TBP at the GAL1 promoter in the pob3 mutant;
binding of both factors is increased in the pob3 set2 strain.
These experiments suggest that yFACT facilitates TBP bind-
ing, at least at some promoters, and Set2 opposes this effect.
How does Set2 inhibit TBP binding at GAL1? One possibility
is that histone methylation by Set2 inhibits binding of a
transcriptional coactivator complex that stimulates TBP bind-
ing. The SAGA complex is recruited to GAL1 and promotes
TBP binding (Dudley et al, 1999). We have analyzed SAGA
binding at the GAL1 UAS by ChIP, but we did not observe any
significant difference in SAGA binding in strains differing at
the POB3 and SET2 loci (data not shown). Chromodomains
bind to methylated histone residues, and it is possible that
methylated K36 residues at the GAL1 promoter encourage
binding of a chromodomain-containing transcription factor
that regulates TBP binding.
Our results strongly support a role for K36 methylation
by Set2 in decreasing TBP binding to promoters. There are
two earlier studies that support a repressive role for Set2 at
promoters. A Set2–LexA fusion protein strongly represses
transcription when tethered to a promoter with a lexA-bind-
ing site (Strahl et al, 2002). This repression by the Set2–LexA
























Figure 7 A set2 mutation suppresses the synthetic lethality of an spt16 mutation with either TBP or TFIIA mutations. (A) Strains DY8552
(indicated as ‘SET2’) and DY10065 (indicated as ‘set2’) were transformed with YCp-TRP1 plasmid encoding a TBP mutant, and dilutions were
plated on complete or FOA medium at 331C for 3 days. (B) Strains DY8700 (indicated as ‘SET2’) and DY10212 (indicated as ‘set2’) were
transformed with a YCp-LEU2 plasmid with the indicated toa2 mutant, and dilutions were plated on complete medium at 251C for 2 days and
on FOA medium at 301C for 4 days, except the TOA2(Y10G,R11D) strains were incubated on FOA medium at 331C.
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catalytic domain. In a separate study, the weak expression
from a GAL4 promoter lacking its UAS element could be
suppressed by either a set2 mutation or a K36R substitution in
histone H3 (Landry et al, 2003). This suggests that Set2 can
repress transcription from promoters.
Set2 and yFACT are believed to function in transcriptional
elongation, although we did not see an effect of mutations on
the elongation rate at one specific gene. Our results strongly
suggest that both Set2 and yFACT function at initiation of
transcription by regulating DNA binding by TBP, at least
at the GAL1 promoter. We previously demonstrated that
spt16 mutants are synthetically lethal with point mutations
in either TBP or TFIIA (Biswas et al, 2005). Importantly,
a set2 mutation can suppress this synthetic lethal interaction.
Additionally, in vitro studies show that yFACT can facilitate
binding of TBP and TFIIA to a nucleosomal TATA site that
is normally refractory to binding (Biswas et al, 2005).
Biochemical studies have shown that the TFIIS factor
(encoded by DST1 in yeast) facilitates elongation by pol II.
However, it was recently shown that TFIIS binds to the
GAL1 promoter (Prather et al, 2005). Additionally, a dst1
mutation affected the kinetics of GAL1 induction, and redu-
ced the association of both TBP and pol II to the GAL1
promoter (Prather et al, 2005), and a further decrease in
promoter occupancy by basal factors is seen when a dst1
mutant is treated with 6-AU (Mason and Struhl, 2005). It has
been suggested that a decrease in elongation slows promoter
clearance, leading to destabilization of the preinitiation com-
plex (Mason and Struhl, 2005). It is intriguing that TFIIS, Set2
and yFACT, all proposed as elongation factors, regulate
binding of TBP at GAL1.
Although a set2 mutation suppresses defects caused by
yFACT mutations, we find that combining a set1 mutation
with either spt16 or pob3 results in synthetic defects. Set1 and
Set2 methylate histone H3 at different residues, K4 and K36,
respectively. A histone H3 K4 substitution enhances yFACT
defects, while a substitution at K36 suppresses these defects.
We examined the epistasis relationships by constructing an
spt16 set1 set2 triple mutant, and by testing a histone
H3(K4R, K36R) double mutant in spt16 and pob3 strains.
The results show that the absence of K36 methylation is not
sufficient to suppress the yFACT mutants. It is the combina-
tion of methylated K4 and unmethylated K36 at histone H3
that suppresses the yFACT defects.
How do the presence or absence of methylated lysine
residues on histone H3 produce such marked effects on
growth of cells with a partially defective yFACT complex?
Chromodomain-containing proteins can bind to methylated
lysine residues. One group has reported that yeast Chd1 binds
to methylated K4 (Pray-Grant et al, 2005), while another
group finds that human, but not yeast Chd1, is capable of
binding to methylated K4 (Sims et al, 2005). It is possible that
in the spt16 H3(K4)R mutant, the lack of binding of a
chromodomain protein, possibly Chd1, is toxic in the pre-
sence of the defective yFACT complex. The Eaf3 chromo-
domain protein has been shown to bind methylated H3 K36
(Carrozza et al, 2005; Joshi and Struhl, 2005; Keogh et al,
2005). Eaf3 is present in two complexes, NuA4 and Rpd3S,
and thus it is possible that the absence of one of these
complexes and their associated enzymatic activities sup-
presses the growth defects of the spt16 and pob3 mutant
strains. It has also been shown that K36 methylation by
Set2 recruits the Rpd3S histone deacetylase complex to the
30 portions of coding regions. In set2 or H3(K36R) mutants,
there could be a redistribution of Rpd3S from coding regions
to promoters, and thus the effect of set2 on TBP binding could
be indirect. Further work will be needed to decipher the
molecular mechanisms of how loss of H3 K36 methylation
suppresses yFACT mutants.
Materials and methods
Yeast strains are listed in Supplementary Table S1. Cells were grown
in YPD medium (Sherman, 1991) at 301C, except where other
temperatures are noted, or in synthetic complete medium (Sher-
man, 1991) with 2% glucose and supplemented with adenine, uracil
and amino acids, as appropriate, to select for plasmids. For the
galactose induction experiments, cells were grown at 251C in YP
medium supplemented with 2% raffinose to mid log, shifted to 301C
for growth for 2 h, and then galactose was added to a final
concentration of 2%. Plasmids are listed in Supplementary Table
S2. The histone mutations were generated by site-directed
mutagenesis, and the sequences verified.
RNA levels were determined with S1 nuclease protection assays
as described (Bhoite and Stillman, 1998) using probes listed in
Supplementary Table S3. Chromatin immunoprecipitations were
performed as described (Ausubel et al, 1987) using the 8WG16
monoclonal antibody against the pol II C-terminal repeat, and a
polyclonal anti-TBP sera generously provided by Tony Weil,
(Schroeder et al, 2000). Real-time PCR and calculations were
performed as described (Eriksson et al, 2004), using the ORF-free
chromosome I region (Mason and Struhl, 2005) as the internal
control.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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